CardAP cells
clinical phase
specialized heart-derived cells
specialized stromal heart cells
clinical study
proprietary cardiac-derived cells
cardiac cell therapy
chronic heart failure
CardAP cell product
unique cardiac-specific stromal cells
progressive chronic cardiac insufficiency
therapy of patients
chronic cardiomyopathy
multicenter clinical trial
technology of CellServe
Achievements Phase
cell product manufacturing
cardiac stress models
cell-based therapies area
severe life-threatening cardiomyopathy
artificial hearts
strong efficacy
life-threatening disease
so-called hospital exemption regulation
rare donor hearts
limited preliminary approval
early market introduction
market ATMP products
Charit√© - University Medicine
key advantages
Mio people
competitors
criteria
experienced management
cure
safety
business plan
bridge devices
leading cause of morbidity
curative therapeutic solution
financial calculations
preparations
year
regulatory requirements
mortality
Commercial potential
Researchers
exclusive license
ATMPs
GMP facilities
Fulfilment
Germany
Equity financing